Compare YDDL & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDDL | PALI |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | Philippines | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.4M | 311.8M |
| IPO Year | 2025 | N/A |
| Metric | YDDL | PALI |
|---|---|---|
| Price | $5.40 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 65.3K | ★ 5.9M |
| Earning Date | 02-23-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 310.92 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $62,922,700.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.00 | ★ N/A |
| Revenue Growth | ★ 118.15 | N/A |
| 52 Week Low | $3.61 | $0.53 |
| 52 Week High | $8.89 | $2.64 |
| Indicator | YDDL | PALI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.65 |
| Support Level | N/A | $2.24 |
| Resistance Level | N/A | $2.55 |
| Average True Range (ATR) | 0.00 | 0.21 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 35.60 |
One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of Philippines. The company process raw materials and generate final products that include copper alloy ingot, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap and industrial recycling. By providing lower-cost alternatives for processing recycled materials, It is not only Contributing to environmental sustainability but also highlight its role as a modern and specialized recycling company.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.